Navigation Links
Molecular Detection Inc. Completes $1.5 Million Financing to Advance New Tests for Sepsis and GI Disorders
Date:3/7/2012

ed that the Detect-Ready MRSA assay is superior to the GeneOhm panel in terms of specificity, while still providing a more rapid screening service compared to traditional microbiology culture methods.

Mr. Wallach continued, "Allowance of the new European patent for our shelf-stabilization technology further enhances the robust intellectual property estate protecting the distinctive advantages of our Detect-Ready technology, complementing our existing European and US patents for our differential diagnosis technology that can analyze multiple gene targets to achieve a highly accurate and informative result." 

The two new test panels being developed by MDI also leverage its differential diagnosis technology.  Sepsis is a potentially life-threatening complication arising from infection, most frequently in hospitalized patients.  Diagnosing sepsis can be difficult and MDI's Detect-Ready sepsis panel is designed to test for a range of targets in order to pinpoint the underlying infection, allowing treatment to begin as soon as possible.  Similarly, patients being treated in institutions are at risk for a variety of serious gastrointestinal infections that can be life threatening and costly.  MDI's Detect-Ready gastrointestinal panel aims to be the first that can distinguish the source of the infection using a single molecular diagnostic test, facilitating timely and effective treatment.  Beta testing for both the Detect-Ready sepsis and GI panels has begun in select healthcare facilities.

All existing investors, including MentorTech Ventures, Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group participated in the $1.5 million financing.

The Detect-Ready MRSA Panel is a qualitative real-time PCR in vitro diagnostic test that is marketed in the European Union (EU) and other territories and is in late-stage development in the US.  It is CE-marked for the detection of MRSA (meth
'/>"/>

SOURCE Molecular Detection Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
2. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
3. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
6. The art of molecular carpet-weaving
7. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
8. Amsterdam Molecular Therapeutics Announces Negative Equity Position
9. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
10. Chemists become molecular sculptors, synthesizing tiny, molecular traps
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... yet often overlooked factor in the medical application ... of aggregation on both radiofrequency heating and magnetic ... nanoparticles (IONPs), including detailed analysis of the aggregate ... shown to produce significant reductions in both heating ... method to quantify and correlate these effects for ...
(Date:9/2/2014)... , September 2, 2014 Persistence ... Membrane Technology in Pharmaceutical, Biopharma and Life Sciences: ... by 2019" the global membrane technology market for pharmaceutical, biopharma and ... 2014 and is expected to grow at a CAGR ... estimated value of USD 10,886.0 million in 2019. ...
(Date:9/2/2014)... 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... and Trademark Office (PTO) has issued a patent related ... weight loss. NB32 is a fixed-dose combination of naltrexone ... Patent No. 8,815,889 claims methods for treating insulin resistance ... expires in 2024. If NB32 is approved for use ...
(Date:9/2/2014)... Rocky Mount, NC (PRWEB) September 02, 2014 ... the establishment of its 11th clinical research site: PMG ... has assumed ownership and operation of the clinical research ... NC, further expanding PMG’s presence in eastern North Carolina. ... 130,000 patients. For the patients in Rocky Mount and ...
Breaking Biology Technology:Accounting for biological aggregation in heating and imaging of magnetic nanoparticles 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... HIGHLIGHTS:2010 Results (all percentages are to comparable periods in 2009) ... a new quarterly high. Q4 sales grew by 2% and 3% ... sales increased 6% and 5% on a reported and currency adjusted ... was $0.76. Excluding restructuring costs of $0.07, adjusted Q4 2010 diluted ...
... new type of biological and chemical sensor that has few ... long-lasting. The "diffraction-based" sensors are made of thin stripes ... contracts depending on the acidity of its environment. Recent ... to precisely determine pH - a measure of how acidic ...
... RATON, Fla., Feb. 8, 2011 Stem Cell Assurance, ... engagement of Marcum LLP to audit its financial statements as ... then ended.  Ranked 15th among the "Top 25 Firms" by ... more than 1,100 professionals, including more than 150 partners, in ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Hydrogels used to make precise new sensor 2Hydrogels used to make precise new sensor 3Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors 2
(Date:9/2/2014)... [Brown University] It,s hard to comprehend how bad ... has become without knowing what it was before people ... rate was 10 times lower than scientists had thought, ... worse. , Extinctions are about 1,000 times more frequent ... came along. The explanation from lead author Jurriaan de ...
(Date:9/2/2014)... that professional baseball pitchers with poor core stability are more ... season because of injury than are pitchers who have good ... In the study, 347 pitchers were assessed for lumbopelvic control ... as they raised a leg to step up were up ... days cumulative, not consecutive during the season than ...
(Date:9/2/2014)... led by researchers at the University of Warwick in ... just published in the Journal Early Human Development ... spent in hospital after birth and the use of ... in preterm children. , Mathematic abilities are crucial for ... in very preterm children. Earlier studies of children who ...
Breaking Biology News(10 mins):Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Mechanical ventilation a key indicator for pre-term children's math problems 2
... detection techniques developed at the University, the team mapped ... and developed a model of their likely distribution as ... action is needed. University of Canberra professor in ... found foxes are widespread in northern and eastern Tasmania ...
... University of Southampton has shown that copper can ... to the increasing number of antibiotic-resistant infections worldwide. ... largely responsible for the development of antibiotic-resistance, which ... healthcare-associated infections (HCAIs). The newly-published paper, which ...
... Institution are rolling out results from the new Airborne ... at the American Geophysical Union (AGU) meetings in San ... uncovering a previously invisible ecological world. To watch a ... the world in a whole new way, click here. ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2New study shows how copper restricts the spread of global antibiotic-resistant infections 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... The TNT Coupled Reticulocyte Lysate ... eukaryotic in vitro translations: a single-tube, ... Systems greatly simplify the process and ... in vitro translation results. Standard rabbit ...
Biology Products: